Andere Sprachen RAPT Therapeutics, Inc.

Aktien

A2PNYQ

US75382E1091

RAPT

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:15:23 30.04.2024			% 5 Tage	% 1. Jan.
7,845 ^USD	-0,44 %		-2,25 %	-68,53 %

09.04.	RAPT Therapeutics gibt vielversprechende Ergebnisse der Phase-2-Studie mit Tivumecirnon in Kombination mit Anti-PD-1-Immuntherapie bei CPI-erfahrenen Kopf-Hals-Krebspatienten bekannt	CI
27.03.	RAPT THERAPEUTICS, INC. : JPMorgan Chase klebt neutral	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09.04.
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09.04.
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09.04.
RAPT Therapeutics, Inc.(NasdaqGM:RAPT) dropped from S&P Biotechnology Select Industry Index	18.03.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT	11.03.
RAPT Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	07.03.
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	07.03.
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting	05.03.
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting	05.03.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT	03.03.
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	26.02.
North American Morning Briefing : S&P 500 Futures -2-	23.02.
RAPT Therapeutics Shares Decline Following UBS Downgrade	22.02.
North American Morning Briefing : Nvidia Ignites -2-	22.02.
North American Morning Briefing : Stock Futures -2-	21.02.
Sector Update: Health Care Stocks Lower Late Afternoon	20.02.
Top Midday Decliners	20.02.
RAPT Therapeutics Shares Plunge Premarket on FDA Study Hold	20.02.
Two RAPT Therapeutics Studies Put on Hold by FDA After Adverse Event	20.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen RAPT Therapeutics, Inc.

Aktien

A2PNYQ

US75382E1091

RAPT

Andere Sprachen

Filter